Perovial®

Medical device

Perovial® is the first intra-penile Hyaluronic acid (HA)-based option in the UK for the management of Peyronie’s disease in its acute phase1.

Click here to find the IFU

perovial hyaluronic acid injection

Highlights

High level of novelty

Classified as a high level of novelty device1

Improvement

Can improve penile curvature, plaque size, and erectile function3,4,5,6

Improves outcome

Improves outcome in terms of penile pain reduction and patients’ satisfaction4,5

Tolerability

Well-tolerated in clinical studies3,4,5

Protocol

Weekly for 10-12 weeks according to the doctor’s professional clinical assessment2

Clinical evidence

Clinical studies show:

Regression in plaque size5,6

Perovial® leads to a measurable decrease in penile curvature3,4,5,6

Perovial® improves erectile function4,5

Perovial® showed significant improvement in penile pain compared to verapamil and baseline and patient satisfaction4,5,6

Perovial® was well-tolerated in clinical studies3,4,5

Contact IBSA

Additional resources

Orchestra conductor directing musical notes, symbolizing the synergy and harmony of therapeutic treatments

Patient Peyronies Disease Booklet

Download
Orchestra conductor directing musical notes, symbolizing the synergy and harmony of therapeutic treatments

Patient Perovial Booklet

Download
Doctor with glasses consulting with a patient in a medical office, symbolizing professional medical advice and trust

HCP Instructions for Use Booklet

Download
Orchestra conductor directing musical notes, symbolizing the synergy and harmony of therapeutic treatments

Patient Treatment Diary

Download
Orchestra conductor directing musical notes, symbolizing the synergy and harmony of therapeutic treatments

Injection Technique

Back to the Perovial® product line

If your patient gets any side-effects, please report them. This includes any possible side effects not listed in the package leaflet. You can also report side-effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

To report a side effect or product complaint to IBSA Pharma please contact IBSA Pharma Ltd on 01923 233466 and medicalinformation.uk@ibsagroup.com.

Section reserved for healthcare professionals

This section contains information intended for healthcare professionals. By continuing, you confirm that you are a healthcare professional authorized to access this content.

Are you a healthcare professional (HCP)?

No, go back

References

  • 1 / European Commission. Expert decision and opinion in the context of the Clinical Evaluation Consultation Procedure (CECP).
  • 2 / PEROVIAL®. Instructions for Use.
  • 3 / Favilla V, et al. Andrology. 2017;5(4):771-5.
  • 4 / Iaconisi GN, et al. Int J Mol Sci. 2023;24(12):10296.
  • 5 / Cocci A, et al. World J Mens Health. 2021;39(2):352-7.
  • 6 / Zucchi A, et al. Sex Med. 2016;4(2):e83-8.
  • 7 / Cai T, et al. World J Mens Health. 2021;39(3):526-32.